SecBot SecBot

ACAD drug pipeline

$18.75
+3.4% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
11
IV 42% · HV 86%
Rated drugs
3
3 neutral
Phase 3 trials
2
1 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed in the US (since March 2023) and EU (since August 2026). Japan regulatory filing planned for 2027 with potential launch in 2028.

DAYBUE trofinetide Updated Nov 6

What to watch

DAYBUE is already approved and generating strong commercial revenue. The next catalyst for this specific drug is the planned Japan regulatory filing in 2027, which could support a 2028 launch, but no hard date is set. Watch quarterly DAYBUE sales growth trajectory and European launch uptake (Germany launched October 2026) as the key near-term value drivers for ACAD stock.

Bull case
  • DAYBUE is the first and only FDA-approved treatment for Rett syndrome, a rare neurodevelopmental disorder with no direct approved competitors, giving it a market monopoly.
  • Q3 2026 DAYBUE net sales surged 39% year-over-year, leading ACAD to raise full-year 2026 guidance to $505-$520 million.
  • European Commission approved DAYBU (trofinetide) on August 24, 2026, opening a new geographic market; Germany launched in October 2026.
Bear case
  • UBS downgraded ACAD from Buy to Neutral in October 2026, reflecting concerns about growth trajectory or valuation.
  • CFO Mark Schneyer sold $69,342 worth of shares on October 30, 2026 at $20.88, a bearish insider signal.
  • The EMA initially refused marketing authorization for Daybu in February 2026 before granting a restricted indication after re-examination, highlighting regulatory risk in new markets.
● neutral
Impact
PhasePhase 3
Time to marketThe Phase 3 RADIANT program's estimated primary completion is January 2028 per ClinicalTrials.gov. If Phase 3 succeeds, an NDA submission would follow, putting a potential FDA decision no earlier than late 2028 or 2029.

remlifanserin Updated Nov 6

What to watch

Watch the CTAD conference (November 16-19, 2026) for detailed Phase 2 data that could shift sentiment. The key binary catalyst is the Phase 3 RADIANT readout, estimated for January 2028. In the interim, Acadia's quarterly earnings and commercial execution of Nuplazid/Daybue will likely drive the stock more than remlifanserin news. A Phase 3 success could open a multi-billion-dollar ADP market; a failure would remove a key pipeline asset but leave Acadia's approved-product revenue intact.

Bull case
  • Remlifanserin targets a large unmet need: there are no FDA-approved treatments specifically for Alzheimer's disease psychosis, which affects an estimated 30-50% of Alzheimer's patients.
  • The Phase 2 data showed a clear dose-response with consistent efficacy trends across multiple scales, and the 60 mg dose achieved nominal significance on the key secondary endpoint (CGI-S-ADP, p=0.0077), supporting the Phase 3 strategy.
  • FDA granted Fast Track designation in July 2026, which can expedite development and review. Acadia has deep regulatory experience with the 5-HT2A mechanism through its approved drug Nuplazid.
Bear case
  • The Phase 2 primary endpoint narrowly missed statistical significance (p=0.0603 vs the 0.05 threshold), raising uncertainty about whether Phase 3 will succeed even with a refined design.
  • Acadia's prior attempt to expand Nuplazid (pimavanserin) into Alzheimer's disease psychosis failed in 2022 when the FDA rejected it for lack of evidence, suggesting the regulatory bar is high for this mechanism in ADP.
  • The Phase 3 program was amended after Phase 2 to drop the 30 mg arm and enrich for more severe patients, which could limit the addressable patient population if approved.
● neutral
Impact
PhasePhase 2
Time to marketIf Phase 2 succeeds, Phase 3 trials would follow, meaning potential FDA approval is likely several years away (probably 2029 or later under an optimistic scenario).

ACP-211 deuterated R-norketamine Updated Nov 6

What to watch

The next catalyst for ACP-211 is the NORLIGHT Phase 2 topline readout, guided for the second half of 2027 (roughly 8-13 months away). A positive efficacy and safety readout would validate the oral deuterated norketamine approach and open a large addressable market in MDD/TRD. A negative or equivocal result would likely end the program but would not threaten ACADIA's core value, which rests on its commercial-stage DAYBUE and NUPLAZID franchises.

Bull case
  • Oral administration is a major differentiator versus Spravato (esketamine nasal spray), which requires in-clinic supervision after each dose, potentially giving ACP-211 a large commercial advantage if approved.
  • Deuteration of R-norketamine is a scientifically rational approach to extend half-life and enable oral dosing in a drug class with proven antidepressant efficacy.
  • ACADIA has a strong commercial infrastructure from DAYBUE and NUPLAZID that could be leveraged for a depression launch, and the company generated $342M in Q3 2026 revenue to fund development without near-term dilution risk.
Bear case
  • Ketamine-class drugs carry known safety concerns including dissociation, abuse potential, and bladder toxicity, which could limit ACP-211's commercial opportunity even if efficacy is shown.
  • The Phase 2 readout is not expected until H2 2027, leaving the stock without a near-term catalyst from this program for roughly a year.
  • ACP-211 is one of several pipeline programs at ACADIA and is not the company's primary value driver, so even a positive readout may have limited impact on the stock price.

Other drugs in filings and trials

no drug report yet

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
CarbetocinOLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromePhase 3Terminated168Dec 19, 2025
CarbetocinStudy of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi SyndromePhase 3Completed · results175Aug 19, 2025